GlassScriptPhysician profile
Dariush Zandi
NPI 1982673976
$13,139.33
in general payments reported to CMS, 2019-2025
48 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,645 · 2020: $2,749 · 2021: $3,253 · 2022: $2,957 · 2023: $1,137 · 2024: $175 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.14 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,671.95 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,285.03 | 2019-2025 | Ubrelvy, Creon, Vraylar |
| Janssen Pharmaceuticals, INC | $1,231.88 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $880.21 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $844.78 | 2019-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.67 | 2019-2025 | Jardiance |
| Pfizer INC. | $590.71 | 2019-2025 | |
| Mylan Specialty L.P. | $490.91 | 2019-2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $428.47 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $427.75 | 2019-2023 | Eliquis |
| Lilly USA, LLC | $375.31 | 2019-2022 | |
| Amarin Pharma, INC. | $345.15 | 2019-2022 | |
| Amgen INC. | $310.57 | 2019-2024 | Otezla, Repatha |
| Allergan, INC. | $306.22 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $289.32 | 2022-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dariush Zandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.